MapLight Therapeutics, Inc.(MPLT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MPLT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for MapLight Therapeutics, Inc. (MPLT), a Healthcare sector company. MPLT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), MapLight Therapeutics, Inc. reports net income of $-60.7M, free cash flow of $-51.2M. Top institutional holders of MPLT by reported 13-F value include Novo Holdings A/S, FCPM III SERVICES B.V., GOLDMAN SACHS GROUP, based on the most recent SEC filings. MPLT trades on the Nasdaq exchange and files with the SEC under CIK 1770069. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MPLT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MapLight Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-60.7M
Free Cash Flow
Q1 2026
$-51.2M
ROIC
Q1 2026
-16.1%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-107.7% YoYOperating Income
-103.8% YoYEPS (Diluted)
+82.4% YoYTotal Assets
+250.2% YoYOp. Cash Flow
-75.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Net Income | $-161.2M -107.7% | $-77.6M | — |
| Operating Income | $-169.1M -103.8% | $-82.9M | — |
| EPS (Diluted) | $-18.56 +82.4% | $-105.38 | — |
| Total Assets | $479.5M +250.2% | $136.9M | — |
| Operating Cash Flow | $-138.1M -75.3% | $-78.8M | — |
AI Insight: MPLT Financial Trends
Pre-revenue biotech burning cash across all three metrics with equity eroding from Q4 2025 to Q1 2026.
• Operating losses narrowed from $83M in Q4 2025 to $65M in Q1 2026; operating cash burn also improved to $51M.
• Shareholder equity declined from $458M (Q4 2025) to $400M (Q1 2026), indicating cumulative losses outpacing any capital raises.
⚠ No revenue visible across any quarter; company remains entirely pre-commercial with limited cash runway at current burn rates.
⚠ Equity position flipped from negative $274M in Q3 2025 to positive $458M in Q4 2025—likely a capital raise; sustainability unclear.
AI Insight: MPLT Ratio Trends
Early-stage biotech with negative returns across all profitability metrics; insufficient operating data to assess underlying business trajectory.
• ROE improved from -69.4% in Q4 2025 to -60.7% in Q1 2026; ROA and ROIC similarly narrowed losses quarter-over-quarter.
⚠ Persistent negative ROE, ROA, and ROIC across both quarters signal ongoing cash burn; no visibility into path to profitability.
⚠ Operating margin, NPM, and leverage ratios unavailable; cannot assess cost structure or financial health comprehensively.
Get alerted when MPLT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for MapLight Therapeutics, Inc. including:
Top Institutional Holders of MPLT
Novo Holdings A/S
$74.9M3,686,622 shFCPM III SERVICES B.V.
$65.6M3,226,400 shGOLDMAN SACHS GROUP INC
$40.6M1,994,873 shBlackRock, Inc.
$27.2M1,339,731 shBlue Owl Capital Holdings LP
$20.5M1,005,929 shNan Fung Group Holdings Ltd
$19.7M971,253 sh5AM Venture Management, LLC
$19.3M950,011 shSanofi
$18.5M912,041 shVANGUARD CAPITAL MANAGEMENT LLC
$14.6M719,820 shPivotal bioVenture Partners Investment Advisor LLC
$12.4M611,447 sh
| Fund | Value | Shares |
|---|---|---|
| Novo Holdings A/S | $74.9M | 3,686,622 |
| FCPM III SERVICES B.V. | $65.6M | 3,226,400 |
| GOLDMAN SACHS GROUP INC | $40.6M | 1,994,873 |
| BlackRock, Inc. | $27.2M | 1,339,731 |
| Blue Owl Capital Holdings LP | $20.5M | 1,005,929 |
| Nan Fung Group Holdings Ltd | $19.7M | 971,253 |
| 5AM Venture Management, LLC | $19.3M | 950,011 |
| Sanofi | $18.5M | 912,041 |
| VANGUARD CAPITAL MANAGEMENT LLC | $14.6M | 719,820 |
| Pivotal bioVenture Partners Investment Advisor LLC | $12.4M | 611,447 |
More Healthcare Companies
View all Healthcare →Put MPLT on your watchlist
Track score changes the day MapLight Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MPLT a good stock to buy?
13F Pro's AI-powered analysis of MapLight Therapeutics, Inc. (MPLT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MPLT are available on the MPLT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own MPLT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MPLT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MapLight Therapeutics, Inc.'s investment landscape.